Elevated levels of Sirt2 in tumor tissues were correlated with poor outcomes for NSCLC patients (Supplementary Fig. 11c), suggesting that Sirt2, as the RRM2 deacetylase, could be a potential prognostic biomarker for NSCLC. Here, SIRT2 is linked to neoplasm.